Sumitomo Chemical came into this earnings print as a low‑expectation value stock, with the share price down about 12% over the past month and sitting near an indicated fair value. The headline today is that profits snapped back hard. Q1 FY2027 basic earnings per share landed at ¥24.70 and net income reached ¥40.8b, flipping from a loss in Q4 FY2026. Trailing twelve month earnings per share moved to ¥64.64, which supports the already low P/E of 7.6x and keeps the stock firmly in the bargain bin of the Japanese chemicals sector.
Is Sumitomo Chemical Company trading at a genuine discount or just wearing the label of a cheap stock for a reason? Compare the low P/E, fair value estimate and risk flags against our valuation analysis for Sumitomo Chemical Company.Q1 2027 Earnings Summary
- Revenue, Q1 2027 vs. Q1 2026: ¥578,199m vs. ¥526,140m (up 9.9%)
- Net Income, Q1 2027 vs. Q1 2026: ¥40,782m vs. a loss of ¥4,523m (very large year on year improvement)
- Basic EPS, Q1 2027 vs. Q1 2026: ¥24.70 vs. a loss of ¥2.76 per share (very large year on year improvement)
- Core Operating Income, Q1 2027 vs. Q1 2026: ¥62.3b vs. ¥27.7b (up 2.2x)
Prefer clean visual charts instead of scrolling through dense tables of figures on Sumitomo Chemical Company? View the full picture of its valuation at a glance in the interactive company report for Sumitomo Chemical Company.
Sumitomo Chemical bullish story meets real margin test
Bulls argue Sumitomo Chemical can turn portfolio cleanup and cost work into higher, more resilient margins rather than just a one quarter bounce. Q1 is a clear proof point on earnings power, with core operating income of ¥62.3b that management calls the second best Q1 on record, but the quality of that beat matters for the thesis.
The margin recovery case leans on Agro & Life, higher value materials and pharma. Agro & Life delivered with core operating income up strongly to ¥9.6b, helped by tighter methionine supply and higher prices, and management sounds confident about meeting first half targets. Semiconductor materials within ICT & Mobility also improved on stronger shipments, aligning with the higher margin materials angle, although overall segment profit slipped due to weaker display films and higher fixed costs. Essential & Green Materials contributed ¥27.2b of core profit, yet much of that came from inventory valuation gains rather than clear structural margin progress.
Compare this internal earnings momentum with external expectations. See whether analysts think Sumitomo Chemical Company deserves a re‑rating at ¥487 or if they still see it as a value trap by checking the consensus price target analysis for Sumitomo Chemical Company.Bear Concerns On Structural Headwinds Mostly Unresolved
Bears argue Sumitomo Chemical sits on eroding legacy demand, rising regulatory costs and slow portfolio transition. The latest quarter gives them fewer easy victories, but it does not close the case. Revenue of ¥578.2b and core operating income of ¥62.3b show the company can still earn money in a tougher setup. However, a big slice of that strength comes from inventory valuation gains in Essential & Green Materials and better margins at Petro Rabigh. That is cyclical help, not clear proof of lasting demand for virgin chemicals.
Where bears focus on slow mix shift and fragile margins, the segment detail still supports caution. ICT & Mobility core profit fell to ¥13.0b as display films weakened and fixed costs rose. Advanced Medical Solutions stayed loss making. Sumitomo Pharma’s core profit of ¥18.8b slipped due to higher R&D and SG&A, which limits how far the portfolio has shifted away from lower quality earnings.
After a quarter where Sumitomo Chemical Company leaned on inventory gains and improving margins, you may want to review whether these are temporary supports or signals of deeper fragility. Scan our independent risk analysis for Sumitomo Chemical Company which shows 3 important warning signsStay Ahead With Simply Wall St
If the sharp swing in Sumitomo Chemical Company’s earnings has your attention, register for free with Simply Wall St and add it to a Watchlist to keep track of share price moves against fair value and wait for the right entry point. After you invest, use the Portfolio Command Center to cut through noise and focus on the most important developments that could affect your holdings. For a broader view, tap into crowd insights and different angles on Sumitomo Chemical Company through the Community. By spotting potential catalysts and risks early, you can make decisions with more confidence and stay ahead of the market.
Seeking Alternatives Beyond Sumitomo Chemical?
Fresh ideas move first when momentum starts building and prices have not yet been caught by the crowd. Scan these focused stock shortlists while it matters and get in early.
- Chase resilient cash flow stories that do not rely on hype by checking the curated list of solid balance sheet and fundamentals stocks (39 results).
- Ride potential income workhorses while yields are still flying under the radar for now with our hand picked 46 dividend fortresses.
- Spot potential growth stories where AI profits are already showing up in the numbers, not just the headlines, by reviewing 68 profitable AI stocks that aren't just burning cash.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com